Enrolling by invitationPhase 2NCT06657859

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

Studying PMM2-CDG

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Glycomine, Inc.
Principal Investigator: Chief Medical Officer
Glycomine, Inc.
Intervention: GLM101(drug)
Enrollment: 90 enrolled
Eligibility: 2 years · All sexes
Timeline: 2024 – 2029

Study locations (2)

Hospital Sant Joan de Déu, Barcelona, Spain, Spain
Great Ormond Street Hospital, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06657859 on ClinicalTrials.gov

Other trials for PMM2-CDG

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06892288
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Glycomine, Inc.
ACTIVE NOT RECRUITINGNCT03173300
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
Glycomine, Inc.

See all trials for PMM2-CDG →

← Back to all trials